FDA removes a major barrier to the use of real-world evidence in medical device reviews

The US Food and Drug Administration (FDA) has issued new guidance that significantly changes how real-world evidence (RWE) can be used in the regulatory review of medical devices. This update removes a long-standing limitation related to the routine submission of identifiable individual patient data when real-world data (RWD) sources are used in certain marketing submissions.

This shift represents a meaningful regulatory advancement for medical device manufacturers and sponsors seeking to support the safety and performance of their devices with evidence generated in real-world clinical settings.

Real-world evidence in medical device

Regulatory background: Real World Evidence (RWE) use in medical devices

Since 2016, the FDA has encouraged the use of Real World Evidence (RWE) use in medical devices as a complement to traditional clinical evidence. In practice, however, its regulatory value has been constrained by strict expectations regarding data granularity and patient-level identification.

Historically, the FDA required RWE submissions to include private, confidential individual patient information, making it impractical to leverage large, aggregated datasets—even when those datasets contained robust information on device performance, safety, and clinical outcomes across broad populations.

Despite these constraints:

• More than 250 medical device premarket authorizations have incorporated RWE.

• The growth of RWE-based device authorizations has plateaued in recent years due to these regulatory barriers.

What the new FDA guidance establishes

Under the new guidance, the FDA clarifies that identifiable individual patient data will not always be required for RWE to be considered in medical device regulatory submissions. Instead, FDA reviewers will assess the quality, relevance, and methodological strength of the RWE on a case-by-case basis.

This approach acknowledges that clinically meaningful insights can be derived from large, de-identified datasets without compromising patient privacy, particularly when analyses are conducted at the population or system level.

Implications for medical device manufacturers

This regulatory change significantly expands evidence-generation options for medical device sponsors:

• Enables the use of large, de-identified clinical databases containing millions of records.

• Facilitates regulatory use of national disease and procedure registries.

• Supports the inclusion of hospital system databases, integrated health networks, and electronic health records (EHR).

• Strengthens safety and performance evidence derived from real-world use, beyond controlled clinical trial environments.

These datasets reflect how devices are actually used across diverse patient populations and real-world care settings, providing insights that are often not captured in traditional clinical studies.

Key regulatory considerations for RWE use

While the FDA has removed the routine requirement for identifiable patient-level data, RWE will continue to be evaluated against rigorous regulatory standards:

• Data source quality, reliability, and traceability.

• Sound study design and analytical validity.

• Appropriate control of bias and confounding factors.

• Clinical relevance to the device’s intended use and indications.

Successful integration of RWE therefore requires a well-defined regulatory strategy and, in many cases, early engagement with the FDA through processes such as Pre-Sub.

Conclusion

The removal of this barrier marks a turning point in the FDA’s regulatory evaluation of medical devices. By allowing broader use of de-identified real-world data, the FDA expands access to meaningful evidence while maintaining patient privacy and scientific rigor.

At Sanrubio,LLC, we support medical device manufacturers in developing regulatory strategies aligned with current FDA expectations, integrating RWE effectively across pathways such as 510(k), De Novo, and PMA submissions.

Ensure Compliance with Sanrubio, LLC

At Sanrubio, LLC, strategically supporting manufacturers from the U.S., Latin America, Europe, and Asia, we offer:

• Medical Device Establishment Registration Renewal

• Personalized regulatory advice: from Pre-Submission design to 510(k) submission (Pre-market notification), De Novo or Breakthrough Devices submission.

• Strategic location: in Miami, key hub for foreign manufacturers entering the U.S. market.

• Free initial consultancy: analyze your case with us and optimize your regulatory strategy.

  
  

Ready to bring your Medical Devices to the U.S. market?

Contact us for a free personalized consult and move ahead with confidence in your regulatory journey.

Contact us

Source: https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews?utm_medium=email&utm_source=govdelivery